Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They presently have a $13.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on MRNS. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 9th. Truist Financial restated a “buy” rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals currently has an average rating of “Hold” and an average price target of $10.25.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $1.55 on Monday. The stock has a 50-day moving average of $1.36 and a 200 day moving average of $2.94. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 12 month low of $1.05 and a 12 month high of $11.26. The firm has a market cap of $85.15 million, a P/E ratio of -0.59 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The company had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. During the same quarter last year, the firm posted ($0.61) EPS. As a group, research analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after buying an additional 85,455 shares in the last quarter. Vanguard Group Inc. grew its holdings in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares in the last quarter. Hussman Strategic Advisors Inc. increased its position in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares during the period. Trexquant Investment LP bought a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $553,000. Finally, Superstring Capital Management LP purchased a new stake in shares of Marinus Pharmaceuticals in the 4th quarter worth approximately $5,027,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.